Viatris (VTRS) News Today $12.52 +0.39 (+3.22%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Viatris Inc. stock rises Friday, outperforms marketDecember 20 at 9:35 PM | marketwatch.comWhat Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn?December 19 at 4:30 AM | insidermonkey.comViatris announces publication of CARE study resultsDecember 19 at 2:08 AM | markets.businessinsider.comViatris Reports Phase 2b CARE Study Data For Cenerimod - Quick FactsDecember 18 at 8:00 AM | markets.businessinsider.comViatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet RheumatologyDecember 18 at 6:59 AM | prnewswire.comViatris Inc. (VTRS) Announces Key Outcomes from 2024 Annual Shareholder MeetingDecember 6, 2024 | gurufocus.comMapi Pharma is Seeking New Depot Product PartnershipsDecember 2, 2024 | globenewswire.comViatris Q3 Earnings TranscriptNovember 28, 2024 | marketbeat.com2 Generic Drug Stocks Ready to Surge in 2025Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.November 27, 2024 | marketbeat.comViatris fined £1.5M for failure to comply with CMA orderNovember 22, 2024 | msn.comUK watchdog fines Viatris $1.9 mln over rule breach in Theramex probeNovember 22, 2024 | reuters.comViatris fined in Morocco over merger notification, sources sayNovember 21, 2024 | reuters.comViatris Inc. (VTRS) Management Presents at Jefferies London Healthcare Conference (Transcript)November 21, 2024 | seekingalpha.comViatris Inc. (VTRS) Jefferies London Healthcare Conference (Transcript)November 21, 2024 | seekingalpha.comViatris Inc. (VTRS) UBS Global Healthcare Conference (Transcript)November 15, 2024 | seekingalpha.comViatris Underperform Rating: Limited Growth Prospects and Conservative Capital Allocation StrategyNovember 9, 2024 | markets.businessinsider.comViatris Inc. (NASDAQ:VTRS) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | msn.comViatris price target raised to $12 from $11 at BarclaysNovember 9, 2024 | markets.businessinsider.comBargain Priced Viatris Reports Strong Q3 Earnings ResultsNovember 8, 2024 | seekingalpha.comViatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ...November 8, 2024 | finance.yahoo.comViatris Inc. Reports Strong Q3 2024 PerformanceNovember 8, 2024 | markets.businessinsider.comViatris Inc. Q3 Profit Decreases, But Beats EstimatesNovember 7, 2024 | markets.businessinsider.comGeneric Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt PaydownNovember 7, 2024 | benzinga.comViatris Tops Analyst Estimates in Q3November 7, 2024 | fool.comViatris nears 11-month high after Q3 beatNovember 7, 2024 | msn.comViatris Inc. (VTRS) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comViatris Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 7, 2024 | seekingalpha.comXanax maker Viatris beats quarterly estimates on demand for new generic drugsNovember 7, 2024 | reuters.comViatris Q3 Earnings Preview: Focus on upcoming product launches and EBITDA growthNovember 6, 2024 | msn.comAre Wall Street Analysts Predicting Viatris Stock Will Climb or Sink?November 6, 2024 | msn.comViatris Announces Third Quarter 2024 DividendNovember 5, 2024 | prnewswire.comViatris to Report Q3 Earnings: What's in the Cards?November 4, 2024 | msn.comViatris Named to Forbes' World's Top Companies for Women 2024 ListOctober 29, 2024 | prnewswire.comViatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare ConferenceOctober 29, 2024 | prnewswire.comIdorsia announces financial results for the first nine months of 2024October 29, 2024 | globenewswire.comEarnings Preview: What To Expect From Viatris' ReportOctober 27, 2024 | msn.comViatris: Promising Financial Outlook with Strategic Share Repurchase and Low Valuation PotentialOctober 16, 2024 | markets.businessinsider.comViatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and EuropeOctober 16, 2024 | prnewswire.comViatris Settles Lawsuit, Avoids Antitrust Charges, and Advances Effexor StudyOctober 16, 2024 | uk.finance.yahoo.comViatris Inc. (VTRS): A Strategic Shift in Healthcare InvestmentsOctober 13, 2024 | msn.comViatris Inc (VTRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic InnovationsOctober 9, 2024 | finance.yahoo.comViatris: EFFEXOR Meets Primary And All Secondary Efficacy Endpoints In Japan - Quick FactsOctober 9, 2024 | markets.businessinsider.comViatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD)October 9, 2024 | prnewswire.comIs Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20?October 8, 2024 | msn.comViatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a RowOctober 8, 2024 | prnewswire.comNovo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: reportOctober 7, 2024 | seekingalpha.comNovo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss DrugsOctober 7, 2024 | msn.comViatris Inc. (VTRS.VI)September 21, 2024 | sg.finance.yahoo.comVTRS Oct 2024 16.000 callSeptember 21, 2024 | ca.finance.yahoo.comVTRS Jan 2025 20.000 callSeptember 21, 2024 | ca.finance.yahoo.com Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Is Starlink Set For The Largest IPO In History? (Ad)He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000! Click here now for the urgent details. VTRS Media Mentions By Week VTRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VTRS News Sentiment▼0.770.61▲Average Medical News Sentiment VTRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VTRS Articles This Week▼53▲VTRS Articles Average Week Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Takeda Pharmaceutical News BioNTech News Teva Pharmaceutical Industries News BeiGene News Moderna News Summit Therapeutics News Genmab A/S News Dr. Reddy's Laboratories News Sarepta Therapeutics News Catalent News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VTRS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
